Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.52 |
| ▸ | TACR1 | P25103 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913502 | 0.92 | HSD11B1 (0.47) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL3811903 | 0.85 | DCUN1D1 (0.58) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| Hydrochloric Acid SCHEMBL21410210 | 0.84 | DCUN1D1 (0.57) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL5399569 | 0.83 | TACR1 (0.48) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL2307172 | 0.82 | DCUN1D1 (0.72) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL6622412 | 0.80 | DCUN1D1 (0.54) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL2233154 | 0.79 | AGER (0.58) | DCUN1D1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL619150 | 0.77 | SLC6A2 (0.71) | DCUN1D1SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL18342235 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL476886 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1265891-B1 | NOVEL LIPOIC ACID HETEROCYCLIC OR BENZENE DERIVATIVES, PREPARATION AND USE THEREOF AS MEDICINES | CONSEILS DE RECH SET D APPLIC (FR) | 2004-12-29 | — | — | EP | disclosed |
| EP-1265891-A2 | NOVEL LIPOIC ACID HETEROCYCLIC OR BENZENE DERIVATIVES, PREPARATION AND USE THEREOF AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068643-A2 | NOVEL LIPOIC ACID HETEROCYCLIC OR BENZENE DERIVATIVES, PREPARATION AND USE THEREOF AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | DCUN1D1 856/4885SLC6A2 2606/4885SLC6A4 2442/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | DCUN1D1 733/4885SLC6A2 2827/4885SLC6A4 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.